Vor Biopharma Inc.

Vor Bio is a clinical-stage biotechnology company advancing therapies that aim to correct autoimmune disease biology, moving beyond symptom control toward lasting improvement. Its lead program, telitacicept, is a first-in-class BAFF/APRIL inhibitor designed to rebalance immunity and deliver consistent clinical benefit. The company is developing telitacicept for autoimmune conditions including generalized myasthenia gravis, Sjögren’s disease, and systemic lupus erythematosus, with the goal of delivering safer, longer-lasting treatments that change patients’ lives.